Events

COST-JRC ‘Science for policy’ seminar
JUN
Mon
28
11:00 - 12:15

This was 4 years ago

Location

Online seminar

Programmes
Joint Research Center COST

COST and the Joint Research Center (JRC) are jointly organizing a seminar on science for policy.

This seminar will highlight the different ways in which researchers try to achieve policy impact. Focusing on how to bring science to the attention of policymakers, the seminar will address tips, recommendations, challenges, lessons learnt, skills and practices outlined in the COST policy brief ‘Actions to Actions’ and the JRC ‘Science for Policy Handbook’.

For more information on this event, agenda and registration please visit the event’s webpage.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.